Physician profile
George P Silis
NPI 1003977422
$10,595.93
in general payments reported to CMS, 2019-2025
50 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $1,460 · 2021: $1,863 · 2022: $1,524 · 2023: $1,554 · 2024: $1,513 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,505 · Entertainment: $34.30 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,505.39 |
| Entertainment | $34.30 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,388.64 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,354.04 | 2019-2025 | |
| Novo Nordisk INC | $876.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $667.69 | 2019-2023 | Belsomra, Dificid, Steglatro |
| Lilly USA, LLC | $654.71 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $563.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $374.64 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $310.11 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $284.33 | 2019-2022 | |
| Glaxosmithkline, LLC. | $284.08 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $283.54 | 2019-2025 | |
| Esperion Therapeutics, INC. | $264.76 | 2020-2022 | |
| Astellas Pharma US INC | $250.60 | 2019-2024 | Veozah, Cresemba, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $206.19 | 2019-2025 | Zoryve |
| Sumitomo Pharma America, INC. | $201.00 | 2023 | Gemtesa |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Silis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.